The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma
Abstract Background There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed c...
Main Authors: | Dao Xin, Yan Song, Lan Mu, Bo Zhang, Ling Qi, Jing Gao, Xingyuan Wang, Jianping Xu, Tao Qu, Jing Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-05-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14885 |
Similar Items
-
Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma
by: Hui Jiang, et al.
Published: (2023-07-01) -
Evaluate the Clinical Outcome of Nanoparticle Albumin-bound Paclitaxel on Breast Cancer Treatment: A Systematic Review and Meta-analysis
by: Yasaman Shariati, et al.
Published: (2022-09-01) -
A case report of hypocalcemia after chemotherapy with albumin‐bound paclitaxel
by: Zhongchao Wang, et al.
Published: (2023-03-01) -
Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01) -
Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes
by: Sei-ichiro Motegi, et al.
Published: (2019-10-01)